Clinical Trial Update: An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)

View source ↗

Summary

An observational study evaluating fecal calprotectin as a clinical tool to monitor moderate-to-severe Crohn's disease in patients on adalimumab induction therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Crohn's Disease | Status: COMPLETED | Results posted: 2015-07-08